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Abstract
Background: Intracytoplasmic morphologically selected sperm injection (IMSI) is still proposed and employed in the
clinical practice to improve the reproductive outcome in infertile couples scheduled for conventional intracytoplasmic
sperm injection (cICSI). The aim of the current randomized controlled trial (RCT) was to test the hypothesis that IMSI
gives a better live birth delivery rate than cICSI.
Methods: Infertile couples scheduled for their first cICSI cycle for male factor were allocated using a simple randomization
procedure. All available biological and clinical data were recorded and analyzed in a triple-blind fashion.
Results: Our final analysis involved the first 121 patients (48 and 73 subjects for IMSI and cICSI arm, respectively)
because the trial was stopped prematurely on the advice of the data safety and monitoring Committee because
of concerns about IMSI efficacy at the first interim analysis. No significant difference between arms was detected
in rates of clinical pregnancy per embryo transferred [11/34 (32.3 %) vs. 15/64 (23.4 %); odds ratio (OR) 1.56, 95 %
(confidence interval) CI 0.62–3.93, P = 0.343] and of live birth delivery [9/48 (18.8 %) vs. 11/73 (15.1 %); OR 1.30,
95%CI 0.49–3.42, P = 0.594).
Conclusion: Current data did not support the routine use of IMSI in the clinical practice for improving cICSI results in
unselected infertile couples with male factor.
Keywords: Intracytoplasmic sperm injection, ICSI, Intracytoplasmic morphologically selected sperm injection, IMSI,
MSOME, RCT
Background
In the assisted reproductive technologies (ARTs), intra-
cytoplasmic sperm injection (ICSI) represents the treat-
ment of choice for couples with male factor infertility
and low or absent fertilization rate in previous conven-
tional in vitro fertilization (IVF) cycles [1]. The ICSI
outcome depends on several factors, including oocyte
quality, patient’s age and the quality of the single
spermatozoa selected to be injected into the oocyte.
This selection is usually performed under an inverted
microscope with magnification of 200×-400×, that al-
lows to detect both motility and normal morphology
of spermatozoa, based on evaluation of their head, neck
and tail. However, this selection revealed many limitations
because of the low magnification used, that permits to
observe only major sperm morphological defects [2].
In order to improve the sperm selection, a new method
of human spermatozoa evaluation called “motile sperm
organelle morphology examination” (MSOME) was sug-
gested [3]. MSOME allows spermatozoa examination at
high magnification (6000× and over) permitting a better
morphological evaluation of acrosome, post-acrosomal
lamina, neck, tail, nucleus, mitochondria [3] and, thus, the
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selection of motile spermatozoa with a morphologically
normal nucleus, normal nuclear content and mitochon-
drial function [4–6]. The integration of MSOME method
into ICSI procedure led to intracytoplasmic morphologic-
ally selected sperm injection (IMSI) [7].
Since the introduction of IMSI twelve years ago, many
studies were published comparing the efficacy of IMSI
respect to cICSI, with conflicting results. That contro-
versial data may be due to the different studies’ design
(comparative, prospective comparative and prospective
randomized studies), the application of heterogeneous
inclusion criteria (maternal age, previous failed ICSI cy-
cles, ovarian response and number of retrieved oocytes,
etc.), and different systems of high magnification sperm
morphology classification adopted [8].
A systematic review with meta-analysis [9] aimed to
compare IMSI with conventional ICSI (cICSI) in couples
with previous cICSI failures or male factor infertility dem-
onstrated improved reproductive outcomes in infertile
couples whom received IMSI. Specifically, in couples with
previous cICSI failures an implantation rate about three-
fold higher [odd ratio (OR) 2.88, 95 % confidence interval
(CI) 2.13–3.89], a pregnancy rate two-fold improved (OR
2.07, 95%CI 1.22–3.50) and a miscarriage rate reduced of
about 70 % (OR 0.31, 95%CI 0.14–0.67) was observed
after IMSI when compared with cICSI [9]. However,
although less evident, the data synthesis demonstrated a
benefit of IMSI over cICSI also in unselected infertile
couple with only male factor [9]. In fact, the implantation
(OR 1.56, CI 1.11–2.18) and pregnancy (OR 1.61, 95%CI
1.17–2.23) rates resulted improved by 50 and 60 %, re-
spectively [9].
Moreover, only few studies comparing the efficacy of
IMSI versus cICSI in a randomized controlled fashion
are available, and with conflicting results [4, 9]. A meta-
analysis [10] of randomized controlled trials (RCTs)
concluded that the current evidence does not support
the clinical use of IMSI since there is no effect on live
birth or miscarriage rate, and that the quality of the sci-
entific evidence for a beneficial effect on the clinical
pregnancy rate is of very low quality.
Notwithstanding that conclusion, increasingly patients
still require an IMSI procedure in case of male factor at
their first IVF cycle in order to optimize their reproduct-
ive results. Based on these considerations, the current
pragmatic RCT was aimed to test the hypothesis that
IMSI gives better reproductive results than cICSI in in-
fertile couples scheduled for their first IVF cycle.
Methods
The present study follows the Consolidated Standards of
Reporting Trials (CONSORT) guidelines and their ex-
tension for nonpharmacological trials [11, 12]. A further
paper’ revision was performed according to the recent
guidelines for infertility trials [13]. All terms employed
followed the International Committee for Monitoring
Assisted Reproductive Technology (ICMART) and the
World Health Organization (WHO) revised glossary on
ART terminology [14].
Protocol
The current study was a single-center triple-blind ran-
domized trial. Specifically, the patients’ enrollment study
was performed from May 2011 to September 2012 at the
Infertility Centre of the ASMN – IRCCS of Reggio Emilia
(Italy). The Infertility Centre of Reggio Emilia is a high-
volume IVF Unit where about 1,500 IVF procedures are
performed yearly.
The Local Ethical Committee approval was not re-
quired because the procedure was commonly employed
in the clinical practice. All couples (female and male
partners) signed an informed consent before the screen-
ing procedures for enrolment. At study design, the trial
was not recorded on any international register available
online. Thus, an international registration number is not
actually available.
After patients’ selection according to inclusion and ex-
clusion criteria, a case history was collected for each
(male and female) patient, all female patients underwent
anthropometric measurements, clinical evaluation, and
pelvic ultrasonography. After ovarian stimulation and
oocyte retrieval, each infertile couple was randomized to
receive in a blinded fashion or standard (i.e., cICSI) or
experimental (i.e., IMSI) IVF procedure. All clinical (in-
cluding safety data and compliance with the treatments)
and biological data were recorded by a researcher
blinded to patients’ allocation. Pregnancies were followed
with a standardized protocol according to National guide-
lines [15] by the same team of obstetricians who did not
know which treatment the patients had received. Obstet-
rical/neonatal data, as well as all pregnancy complications,
were carefully recorded [13]. A follow-up of the offspring
was planned at one year of age to assess the health of
babies (and to assess congenital abnormalities, long-term
effect of pregnancy complications, developmental delays,
and so on) [13].
All procedures, drugs, culture media, instruments and
visits performed and used during the study were defined
at study design and were the same for each couple. It
was planned that all oocytes pick-ups and embryo trans-
fers should be performed by the same operator (GBLS).
Study population
Eligible participants were all couples scheduled to their
first ICSI cycle for male infertility with ejaculated fresh
sperm. However, the decision of whether to perform IVF
or ICSI was definitively made upon sperm quality ana-
lysis performed after oocyte pick-up. Specifically, a
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percentage of spermatozoa with normal morphology less
than 4 % [20] and/or a number of activated spermatozoa
1.5 106/ml after capacitation were considered inclusion
criteria. A concentration of activated motile sperm less
than 0.1×106/mL after swim-up technique, and the use
of cryopreserved or surgically retrieved semen were con-
sidered exclusion criteria. No other specific exclusion
criteria (including a female age > 40 years) was used.
Randomization
Eligible participants were allocated randomly to two in-
dependent arms (cICSI and IMSI arm) using a simple
randomization procedure [16]. Specifically, couples were
allocated to one of two groups according to the last
number of numeric code of the female partner’s identity
document (e.g. even-ICSI group and odd-IMSI group).
To simplify the blinding procedures, the randomization
was performed in the laboratory just before the ICSI pro-
cedure. The modality of the randomization was known
only to the physician who performed the initial selection
and recruitment of couples and was kept hidden from the
team for the entire duration of the study. The resulted
block size was variable. The random allocations were con-
cealed in closed dark envelope until the end of the study.
All clinicians, investigators, assessors, and patients
remained blinded to the treatment assigned until the
end of the study. Data analysis was also performed
by a researcher who did not know couples’ allocation
(triple-blind).
Interventions
Controlled ovarian stimulation and oocyte retrieval
Controlled ovarian stimulation protocols and oocyte re-
trieval are described elsewhere [17]. Briefly, after ovarian
down regulation, obtained with a long luteal leuprolide
acetate depot protocol (Enantone 3.75 mg; Takeda, Milan,
Italy), recombinant follicle-stimulating hormone (rFSH;
Gonal F; Serono, Rome, Italy) was administrated using a
starting dose (first five days) tailored according to patient’s
age and antral follicle count (ranged from 112.5–450 IU/
day). From day 6 of ovarian stimulation, the ovarian re-
sponse was monitored by transvaginal ultrasonography
and serum estradiol (E2) assay every 3 days up to the
appearance of dominant follicles with a mean diameter of
at least 12 mm and, then, daily. The dose of rFSH was
adjusted according to the ovarian response. When one or
more > 17 mm in diameter were obtained, the ovula-
tion was triggered by injection of 10,000 IU human chori-
onic gonadotropin (hCG) 24 h after the last injection of
rFSH, and 36 h later oocyte retrieval was performed by
ultrasound-guided transvaginal aspiration. The cycle was
canceled in patients at high risk for ovarian hyperstimula-
tion syndrome (OHSS) [18], whereas a low ovarian
response was not considered an indication to cancel the
cycle.
Semen preparation, sperm selection and oocyte injection
Semen samples were collected by masturbation after 3–
5 days of ejaculatory abstinence and evaluated according
to the threshold values established by last WHO manual
[19]. Sperm morphology was evaluated according to strict
Kruger criteria [20]. Semen preparation was performed as
previously described [17]. Briefly, after liquefaction semen
sample was diluted with 10 mL of buffer medium (G-
MOPS Plus; Vitrolife, Gothenburg, Sweden) and cen-
trifuged 10 min at 800× g at room temperature. After
supernatant removal, the pellet was diluted with 5 mL of
buffer medium and centrifuged 10 min at 800× g at room
temperature. The supernatant was removed and the pellet
was overlaid with 1 mL of medium (G-IVF Plus; Vitrolife,
Gothenburg, Sweden) and incubated at 37 °C, 6 % CO2 in
air to separate by swim up. In case of semen with sperm
concentration < 1 × 106/mL, the sample was concentrated
by one centrifugation at 1500× g and the pellet removed
in 1 mL of medium.
cICSI procedure was performed 3 h after the oocyte re-
trieval in a plastic dish of 50 mm × 9 mm (Ref. 351006;
BD Biosciences Labware, Belgium) with 5 μl microdro-
plets (G-MOPS Plus; Vitrolife, Gothenburg, Sweden) for
oocyte injection and a droplet of polyvinylpyrrolidone
droplet (PVP; Vitrolife, Gothenburg, Sweden) covered
with mineral oil (Ovoil; Vitrolife, Gothenburg, Sweden).
An aliquot of sperm suspension was added to PVP for the
search and capture of spermatozoa selected for injection.
cICSI was performed with an inverted microscope (TE
2000 U; Nikon Corp., Tokyo, Japan) equipped with a
heated stage (37 °C) and the Hoffman modulation
contrast under ×200 magnification [21]. In case of
cICSI, the embryologist excluded spermatozoa exhibit-
ing severe morphological defects with particular re-
gard for the head.
All IMSI procedures were always performed by only
one experienced and trained operator (BV) in order to
limit the inter-operator variability of selection. IMSI
started 1 h after the oocyte retrieval and was performed
at room temperature with the same inverted microscope
(TE 2000 U, Nikon Corp., Tokyo, Japan) equipped with
Normarski optics (×60) enhanced by a videozoom, and
digital imaging was used to obtain a magnification of
×7000. Firstly, an aliquot of sperm suspension was added
to a PVP droplet (PVP; Vitrolife, Gothenburg, Sweden)
covered with mineral oil (Ovoil; Vitrolife, Gothenburg,
Sweden) within a glass-bottomed dish (Will Co. Dish®
Gwst 5040, Amsterdam, The Netherlands). The evalu-
ation and capture of the spermatozoa was performed as
described by Bartoov et al. [7, 22], that defined as a
“normal” the spermatozoa nuclei with normal-shaped,
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smooth, symmetric, with oval configuration, and with
nuclei presenting a homogeneous nuclear chromatin
mass, without regional nuclear disorders and containing
no more than one vacuole which occupies less than 4 %
of the nuclear area.
No adjustment of the sample temperature and the
PVP concentration was made [23]. Moreover, consider-
ing data showing a deleterious effect of the sperm
manipulation after 2 h [24], it was planned that, if no
spermatozoa with normal nuclei were available, the “sec-
ond best” and the “third best” morphologically evaluated
spermatozoa would be retrieved after the first 60 min
and 75 min, respectively, hour in order not to complete
the sperm collection for IMSI procedures within 1 h and
30 min. In this case, the spermatozoa captured could
present a small or large oval nuclear shape with mor-
phologically normal nuclear content (first choice), a
non-oval, abnormal nuclear shapes but with normal nu-
clear content (second choice) or a regional shape dis-
order (third choice) [25]. Sperm cells exhibiting large
nuclear vacuoles but with normal oval nuclear shape
were considered preferable for selection to those with
combined nuclear malformations [25]. Before the injec-
tion, the selected sperm were immobilized and incu-
bated for 30 min (at 37 °C, 6 % CO2).
For cICSI and IMSI procedures, the oocytes were denu-
dated and the metaphase II (MII) oocytes were injected
within 3 h from oocyte retrieval. Then, the injected oo-
cytes were transferred into 30 μL droplets of culture
medium (G1; Vitrolife, Gothenburg, Sweden), covered
with mineral oil (Ovoil; Vitrolife, Gothenburg, Sweden)
and incubated at 37 °C (6 % CO2 in air).
Fertilization, embryo cleavage and embryo quality
assessment
Oocyte fertilization was assessed 18–20 h after injection
[17]. Embryo cleavage and quality were evaluated 48–72
h after injection. For each embryo we evaluated the fol-
lowing parameters: number and regularity of blastomeres
(shape and dimension), percentage of fragmentation, ap-
pearance of the cytoplasm, symmetry of cleavage and
presence and numbers of nuclei [26]. Specifically, embryos
characterized by blastomeres having regular shape and di-
mension, absence of fragmentation and homogeneous
cytoplasm without vacuoles and granulation were classi-
fied as grade I and considered top-quality embryos; em-
bryos characterized by regular or slightly irregular shape
and/or dimension of blastomeres, absence of fragmenta-
tion and homogeneous cytoplasm with no more than
10 % of fragmentation as grade II; embryos characterized
by irregular shape and/or dimension of blastomeres, frag-
mentation variable between 10–30 % as grade III; and
embryos characterized by irregular shape and/or di-
mension of blastomeres, cytoplasmic fragmentation
between 30 –50 %, blastomeres with dark or granulose
cytoplasm or with numerous vacuole as grade IV; em-
bryos characterized by indistinguishable or degenerated
blastomeres, more than 50 % of fragmentation, very dark
cytoplasm or high vacuolation or non-developing embryos
as grade V [26].
Embryo transfer
Embryo transfer was performed 48–72 h after insemin-
ation at stage of 4–8 cells by the same operator (GBLS).
The number of cleavage embryos to transfer was estab-
lished according to our internal guidelines based on fe-
male age and semen quality. Specifically, in patients with
female age < 38, 38–39 and 40–42 years old were trans-
ferred 2, 3 and 5 embryos, respectively. In case of sperm
concentration < 1 × 106/mL, in patients with <38 and
38–42 years old were transferred 3 and 5 embryos, re-
spectively. All supernumerary embryos, as well as those
of patients at risk for OHSS, were cryopreserved, and
transferred two cycles later in case of first IVF failure.
All patients undergoing embryo transfer received sup-
plemental progesterone vaginally (400 mg/day for 15 days;
Prometrium, Rottapharm, Milan, Italy).
Main outcome measures
The primary endpoint of the current clinical trial was the
live birth delivery rate. The secondary endpoints were the
rates of total live birth delivery, healthy baby-in-arm, clin-
ical pregnancy rate, as well as the fertilization rate, the
good quality embryos rate, the implantation and the mis-
carriage rates. Other secondary endpoints were the OHSS
and multiple pregnancy rates, the incidence of pregnancy
complications, the rate of compliant patients who re-
peated the IVF procedure after failure.
The live birth delivery rate was defined as the number
of deliveries that resulted in at least one live born
expressed per initiated (patient), aspirated and embryo
transfer cycles [14]. The total live birth delivery rate was
defined as the number of deliveries that resulted in at
least one live born expressed per 100 couples including
all fresh cycles and all frozen/thawed ART cycles [14].
The total healthy baby-in-arm rate was arbitrary defined
as the number of healthy babies at one-year follow-up
per 100 couples (including all ART cycles per patient).
The clinical pregnancy rate was defined as the number
of clinical pregnancies expressed per 100 initiated, aspi-
rated and embryo transfer cycles [14].
Pregnancy was initially determined 12 days after em-
bryo transfer by a positive quantitative serum βHCG
assay > 10 IU, followed by another quantitative βHCG
after 2–4 days to ensure the appropriately rising levels
or to confirm the negative result. Clinical pregnancy was
defined as at least one fetus with a positive heart beat
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revealed by transvaginal sonography 4 or 5 weeks after
embryo transfer [14].
Fertilization rate was expressed as the number of 2PN
zygotes obtained divided by the number of inseminated oo-
cytes; the percentage of good quality embryos obtained
was expressed as the number of good quality embryos ob-
tained divided by the total number of embryo obtained; the
implantation rate was defined as the number of gestational
sacs observed divided by the number of embryos trans-
ferred; the miscarriage rate was expressed as the number
of miscarriage occurred before 20 weeks of gestational age
divided by the number of clinical pregnancies [14].
Other secondary endpoints regarded the pregnancy/
maternal and perinatal/neonatal outcomes. Specifically,
for each pregnant women were recorded the weight
gain, the pregnancy complications (pregnancy-induced
hypertension, pre-eclampsia, gestational diabetes melli-
tus, and so on), the mode of delivery, and the intrapar-
tum complications (hemorrhagia, shoulder dystocia,
and so on). For each born, the following data were
noted: gestational age at delivery, birth weight, neonatal
growth, sillbirth or neonatal death, Apgar score, admission
to neonatal intensive care unit, perinatal/neonatal compli-
cations (respiratory distress syndrome, hypoglycemia,
hyperbilirubinemia, and so on), breastfeeding and its dur-
ation. At one follow-up, for each baby a neonatologist
searched/excluded anatomic anomalies, neurological defi-
cits, and any generic neonatal disease.
Statistical analysis
The goal of the proposed superiority study was to test
the null hypothesis that in infertile couples with male
factor the live birth delivery rate is higher after IMSI
than after cICSI. The criterion for significance (alpha
error) was set at 0.05. The test was two-tailed, which
meant that an effect in either direction would be inter-
preted. Considering previous RCT showing live birth
data [27], the rates of live births for patients
Fig. 1 Trial flow-chart according to the CONSORT guidelines [12, 13]
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undergoing IMSI and cICSI procedure were approxi-
mately 0.44 and 0.38, respectively. Thus, we needed to
enroll at least 179 patients in each arm to yield a statis-
tically significant result with a power (beta error) of
80 %. To allow for an unpredictable number of with-
drawals, we decided to enroll a total of at least 200 pa-
tients per arm in the expectation that at least 179
patients would remain. At study design, interim ana-
lyses were planned (one every five months) in order to
monitor the safety of the experimental procedure and
recalculate the sample size. The power analysis and the
calculation of sample size were performed using Sam-
plePower, release 2.0.
Data were analyzed using the intention-to-treat (ITT)
method on the basis of the treatment assignment. The
normal distribution of continuous variables was evalu-
ated using the Kolmogrov-Smirnov test. Continuous
data were expressed as the mean ± standard deviation
(SD) or as median and interquartile range (IQR) with
min-max values. Difference between arms were ana-
lyzed by Student t test for unpaired data or with
Mann–Whitney U test, as appropriate. For categorical
variables, the Pearson Chi square test was performed;
Fisher’s exact test was used for the frequency tables
when more than 20 % of the expected values were
lower than five.
Cox proportional-hazards model was used to calcu-
late the OR and its 95 % CI for the most relevant clin-
ical endpoints (StatsDirect, release 2.4.3). The number
need to treat (NNT) was calculated for the primary
endpoint. The level of statistical significance was set at
P < 0.05 for all statistical analyses. The Statistics Pack-
age for Social Sciences (SPSS 15.0.1, 22 November
2006; SPSS Inc., Chicago, IL, USA) was used for all
calculations.
Results
In Fig. 1 is showed the study flow-chart according to the
CONSORT guidelines [12, 13]. The patients’ enrolment
was stopped prematurely in September 2012 on the
advice of the data safety and monitoring Committee
because of concerns about IMSI efficacy at the third in-
terim analysis. In fact, a significant and unexpected
lower fertilization rate was observed in IMSI arm when
compared to cICSI arm. Thus, our final analysis involved
the first 121 patients (73 and 48 subjects for cICSI and
IMSI arm, respectively) who had been enrolled and ran-
domized. Moreover, pregnant patients were followed up
to June 2013 and the follow-up of the offspring was
closed in July 2014.
As showed in Table 1 the IMSI and cICSI groups
were similar in terms of male and female ages. There
was no difference between the two arms also in terms
of body mass index (BMI), stimulation length, gonado-
tropins dose administered, number of dominant follicles
and peak of E2 levels on day of ovulation triggering
(Table 1). The rate of patients with severe male factor
(sperm count <1×106/mL) was also not significantly dif-
ferent between two groups [9/73 (12.3 %) and 6/48
(12.5 %) subjects for cICSI and IMSI arm, respectively;
P = 1.000].
No statistically significant differences between IMSI
and cICSI arms in terms of baseline semen parameters,
and number of retrieved oocytes, number of MII retrieved
oocytes and number of inseminated oocytes was observed
(Table 2). In 160/219 (73.0 %) spermatozoa with normal
nuclei were used for IMSI. In 33/219 (15.1 %), 21/219
(9.6 %) and 5/219 (2.3 %) of cases, the first, the second
and the third choice spermatozoa selected were used for
IMSI (Table 2). Only in four cases [4/48; (8.3 %)] no
spermatozoa with normal nuclei were available for micro-
injection in IMSI group.
The fertilization rate, as well as the number of embryos
obtained, number of embryo transfers performed and the
mean number of embryos transferred, were significantly
higher in the ICSI arm. The percentage of good quality
embryos obtained was similar in the two study arms
(Table 2).
No significant difference between study arms was de-
tected in any of the other main outcome measures; spe-
cifically, the delivery live birth rates per initiated cycles
[9/48 (18.8 %) vs. 11/73 (15.1 %) for IMSI and cICSI
arms, respectively; P = 0.624] and per embryo transfer
[9/34 (26.5 %) vs. 11/64 (17.2 %) for IMSI and cICSI
arms, respectively; P = 0.301] were not significantly
Table 1 Clinical characteristics of two study arms
IMSI cICSI P
Number of couples 48 73 -
Female age 35.4 ± 4.2 36.1 ± 4.1 0.365
Male age 39.3 ± 6.0 37.7 ± 6.0 0.154
Female BMI 22.9 ± 3.4 23.4 ± 4.5 0.513
Duration of the infertility (mo) 19.5 ± 5.1 18.2 ± 3.9 0.116
Primary infertility (n.; %) 44/48; 91.7 70/73; 95.9 0.434
Co-causes of infertility
Oligo-anovulation (n.; %) 12/48; 25.0 16/73; 21.9 0.826
Tubal factor (n.; %)a 4/48; 8.3 6/73; 8.2 1.00
Stimulation length (days) 12.9 ± 4.0 13.2 ± 3.3 0.654
Gonadotropins dose (IU) 2169.9 ± 1077.5 2536.8 ± 1534.1 0.153
Dominant follicles on day
of ovulation triggering (n.)
5.6 ± 2.6 4.9 ± 2.7 0.160
Peak of E2 levels on day
of ovulation triggering (pg/mL)
1356.3 ± 724.8 1255.0 ± 720.6 0.453
Data expressed as mean ± SD. BMI: body mass index. ain no case unilateral/
bilateral hydrosalpinges was detected at ultrasonography
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different (Table 2). The ORs for the delivery live birth
rates per initiated cycles and per embryo transfer were
1.30 (95 % CI 0.49 to 3.42, P = 0.594), and 1.73 (95 % CI
0.64–4.62, P = 0.281; respectively. The NNT for IMSI
procedure was of 28 benefits. Reproductive data after in-
clusion of frozen IVF cycles did not change significantly
our findings (Table 2). No effect of the specific IVF pro-
cedure used was detected on further fertility treatments
[43/48 (89.6 %) vs. 56/73 (76.7 %) for IMSI and cICSI
arms, respectively; P = 0.093].
Obstetrical e neonatal data were not significantly dif-
ferent between the two study arms (Table 3).
All biological and clinical data obtained resulted not
influenced by severe male factor infertility, different op-
erator (for cICSI) and patient’s BMI (data not shown).
Discussion
The purpose of this RCT was to verify in our clinical
practice the impact of the use of IMSI in couples who
attempted at their first ICSI cycle for male factor. In this
view, only couples with sperm concentration less than
0.1×106/ml after semen preparation were excluded from
this study in order to have a sufficient number of sperm-
atozoa to perform an effective selection, whereas no spe-
cific criteria was used for selecting female subjects.
Obviously, in our study population a consistent propor-
tion of patients was aged more than 38 years and/or
poor responders. This translated with a low reproductive
performance in both arms with particular regard for the
rates of fertilization.
Our data demonstrated that IMSI procedure did not
improve the reproductive outcomes in infertile couples
scheduled for cICSI. In particular, no significant differ-
ence was detected for live birth delivery rate, our pri-
mary endpoint. Current results confirm those obtained
in two previous RCTs on unselected populations of in-
fertile couples [27, 28]. Moreover, the Leandri’s study
[28] had a multicenter design with a number of biases
and confounders [11], and included only female patients
younger than 39 years and day 3 FSH level lower than
9 IU/L. The data synthesis of these two studies [27, 28]
with the current demonstrates no clinical benefit of
IMSI over cICSI (Fig. 2). Specifically, IMSI resulted in a
significantly higher rates of implantation (OR 1.40,
CI95% 1.06–1.88, P = 0.02) with moderate heterogeneity
Table 2 Biological and clinical outcomes of two study arms
IMSI (n. 48) cICSI (n. 73) P
Sperm count (million/ml) 22.6 ± 24.6 22.9 ± 23.7 0.947
Motility (% total count) 29.6 ± 16.0 24.5 ± 12.8 0.055
Morphologically normal
spermatozoa (% total count)
2.9 ± 2.2 2.8 ± 2.3 0.812
Sperm morphology by MSOME criteria (n., %)
Normal nuclei 160/219; 73.0 — —
First choice selected sperm 33/219; 15.1 — —
Second choice selected sperm 21/219; 9.6 — —
Third choice selected sperm 5/219; 2.3 — —
Aspirated cycles (n.) 48 73 —
Retrieved oocytes (n.) 6.3 ± 2.7 6 ± 3.5 0.6157
MII oocytes retrieved (n.) 5.1 ± 2.5 5.3 ± 3.1 0.709
Oocytes inseminated (n.) 4.6 ± 1.9 4.6 ± 2.8 1.000
Fertilization rate (n.; %) 105/219; 47.9 211/333; 63.4 0.001
Embryo obtained (n.) 99, 2.1 ± 1.7 221, 3.0 ± 1.9 0.009
Good quality embryos
rate (n.; %)
73/99; 73.7 167/221; 75.6 0.834
ET rate (n.; %) 34/48; 70.8 64/73; 87.7 0.038
Embryo transferred (n.) 65, 1.4 ± 1.0 137, 1.9 ± 1.2 0.018
Implantation rate (n.; %) 15/65; 23.1 18/137; 13.1 0.102
Total pregnancies (n.) 14 19 —
Total pregnancy rate//initiated
cycles (n.; %)a
14/48; 29.2 19/73; 26.0 0.865
Total pregnancy rate/ET (n.; %) 14/34; 41.2 19/64; 29.7 0.952
OHSS rate (n.; %) 5/48; 10.4 6/73; 8.2 0.930
Biochemical pregnancy rate (n.,
%)
3/14; 21.4 4/19; 21.1 0.859
Clinical pregnancies (n.) 11 15 —
Clinical pregnancy rate/initiated
cycles (n.; %)*
11/48; 22.9 15/73; 20.5 0.823
Clinical pregnancy rate/ET rate
(n.; %)
11/34; 32.3 15/64; 23.4 0.349
Miscarriage rate (n.; %) 2/11; 18.2 4/15; 26.7 1.000
Multiple pregnancies
rate (n.; %)
4/11; 36.4 4/15; 26.7 0.683
Delivery live births (n.) 9 11 —
Delivery live birth rate/initiated
cycles (n.; %)*
9/48; 18.8 11/73; 15.1 0.624
Delivery live birth rate/ET
(n.; %)
9/34; 26.5 11/64; 17.2 0.301
Twin deliveries 2/9; 22.2 4/11; 36.4 0.496
Live births 11 14
Cycles with embryo freezing 9/48; 18.8 13/73; 17.8 0.895
Embryo thawing cycles 9 7 ——
Embryo thawing ET 6/9; 66.7 5/7; 71.4 0.839
Embryo thawing clinical
pregnancies
0/6; 0 2/5; 40 0.186
Table 2 Biological and clinical outcomes of two study arms
(Continued)
Embryo thawing deliveries 0/6 1/5; 20 0.528
Total delivery live birth rate/
initiated cycle (n., %)
9/48; 18.8 12/73; 16.4 0.743
Data expressed as mean ± SD or as number/percentage. MII metaphase II,
MOSOME motile sperm organelle morphology examination, PU pick-up, ET
embryo transfer, OHSS ovarian hyperstimulation syndrome, aBecause no cycle
was cancelled, the initialled cycles corresponded to the aspirated cycles
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(I2 = 33 %) but no significant difference in terms of clin-
ical pregnancy rates and, most important, live birth rates
was observed (OR 1.12, 95 % CI 0.78–1.61, P = 0.53 with
I2 = 0 % and OR 1.04, 95 % CI 0.72–1.52, P = 0.83 with
I2 = 0 %; respectively).
Although in the current trial no effect on all biological
and clinical data was detected by severe male factor infer-
tility, at the moment, it cannot exclude that IMSI could
have a beneficial effect in selected couples. After data sub-
analysis, Balaban et al. [27] demonstrated an higher im-
plantation rate after IMSI in couples with severe male fac-
tor infertility suggesting that the IMSI technique could
exert some benefit for selected couples. In the first RCT
published by Antinori and co-workers, IMSI significantly
increased the implantation and the clinical pregnancy
rates, particularly in couples with two or more cICSI fail-
ures [29]. Other recent non-randomized studies demon-
strated that IMSI could improve clinical outcomes in
couples with teratozoospermia [30, 31], even if no benefit
of IMSI in infertile couples with isolated male factor and
at least six oocytes available on retrieval was demonstrated
in a RCT [32]. In fact, the absolute difference in clinical
pregnancy rate between IMSI and cICSI was less than 1 %
(36.8 % vs.37.2 %, respectively) [32]. After data subanalysis,
better results were obtained in patients with oligoasthe-
noteratozoospermia defined according to 2010 WHO
references values [32]. However, those results were
not obtained in a randomized populations resulting
potentially biased by several confounders [32]. Finally,
more recently, IMSI was also studied in couples with
women with poor ovarian response to gonadotropin
stimulation [33] or with advanced age [6]. In particular,
poor responders did not benefit from sperm selection
under high magnification prior to ICSI [33], whereas IMSI
resulted in an improved embryo quality and in a 9-fold in-
crease in the clinical pregnancy rate in selected couples
with advanced maternal age and good ovarian response
[23].
Overall, our data show slight differences between
cICSI and IMSI in terms of biological result, such as the
fertilization rate, the number of embryos obtained, num-
ber of embryo transfers performed and the mean num-
ber of embryos transferred. These results do not depend
on differences in semen and oocytes characteristics, as
well as in the percentage of couples with severe male
factor infertility. An effect of morphology of spermato-
zoa selected for IMSI can be excluded. In fact, only in
few cases were not available spermatozoa with normal
nuclei for microinjection. An effect of the time can be
excluded too. In fact, all IMSI procedures were com-
pleted within 90 min, as defined in the study protocol.
The risk for a damage of the sperm membrane due to
PVP exposure [34] was minimized in our study. Not-
withstanding we limited the time of sperm selection, in a
very high proportion of cases the “best” one spermato-
zoa was injected. To this regard, it is well known that
the injection of spermatozoa with morphological defects
significantly reduces the fertilization rate, the percentage
of top-quality embryos obtained, the implantation and
the clinical pregnancy rates [25, 35].
A significant effort was to assess the impact of IMSI
procedure on other ancillary secondary endpoint. Firstly,
no beneficial or worsening impact of the IMSI can be sus-
pected on the compliance of the couples to further fertility
treatments. Secondly, no effect of IMSI was observed on
the incidence of obstetric complications and on pregnancy
outcome, including maternal and neonatal/fetal outcomes.
Moreover, our data cannot exclude higher (or lower) birth
defects and epigenetic diseases. To this regard, only one
peer-reviewed study was published on the incidence
of major congenital malformation of 1028 children born
after IMSI or cICSI [36]. A reduced risk for major birth
defects was observed after IMSI, also after multivariate ad-
justment for confounding factors [36]. That result con-
firmed a preliminary non-peer-reviewed report on a small
sample, not published further in extension [37].
Current RCT has specific strengths and limitations.
The strengths regard the study design, setting care given,
and the lack of patients’ selection. It had a prospective
randomized design with patients blinded to the proced-
ure received and assessors blinded to the patients’ alloca-
tion. The setting was a high-volume center for IVF
Table 3 Obstetrical e neonatal data in the two study arms
IMSI (n. 48) cICSI (n. 73) P
Maternal outcomes
Pregnancy complications (n.; %) 4/9; 44.44 1/12; 8.33 0.080
Mode of delivery
Spontaneous delivery (n.; %) 5/9; 55.55 6/12; 50 0.801
Instrumental delivery (n.; %) 1/9; 11.11 1/12; 41.67 0.831
Caesarean delivery (n.; %) 3/9; 33.33 5/12; 36.36 0.698
Intrapartum complications (n.;
%)
1/9, 11.11 1/12, 9.09 0.831
Neonatal outcomes
Gestational age at delivery
(weeks)
36.25 ± 2.77 38.03 ± 1.58 0.077
Preterm delivery (n.; %) 2/9, 22.2 2/12, 16.7 0.749
Birth weight (g) 2535.00 ±
710.00
2789.37 ±
575.24
0.492
Apgar score at 5 min 8.80 ± 0.45 9.33 ± 0.82 0.211
Admission to NICU (n.; %) 2/11; 18.18 1/15; 7.14 0.382
Breastfed babies (n.; %) 1/11; 9.09 1/15; 7.14 0.819
Duration of breastfeeding
(months)
6.33 ± 5.13 6.6 ± 5.08 0.906
Congenital anomalies (n.; %) 2/11; 18.18 0 0.190
Data expressed as mean ± SD or as number/percentage. NICU neonatal
intensive care unit
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procedures, and the biologists were specifically trained
and certified for both procedures. Our primary endpoint
was the live birth rate, albeit a one-year follow-up was
initially planned to confirm the health of the babies born
[13]. In addition, our study was performed on unselected
couples at their first IVF cycle. In fact, according to the
definition of pragmatic trial, in our opinion the use of
no specific exclusion criteria for female partner must be
considered a study’ strength since our sample was totally
representative of population of couples referring for an
IVF cycle for male infertility. Moreover, our study had
also limitations essentially due to little sample size and
the unbalanced number of patients allocated in the IMSI
and cICSI groups. In fact, the current clinical trial was
prematurely stopped at the first interim analysis. The
need to stop a study protocol after negative data on
intermediate endpoints can be issue of discussion. How-
ever, this induced a loose of study’ power and accuracy to
drawn definitive conclusions. In addition, it could have re-
duced the effect of randomization in reducing the selec-
tion bias balancing the arms with respect to many known
and unknown confounding or prognostic variables. Fur-
thermore, the simple randomization seemed to be still ef-
fective since the two study arms resulted homogeneous
for all clinical and biological parameters assessed and any
statistical correction was need.
Conclusion
Current data suggests that IMSI did not improve any re-
productive outcome in unselected infertile couples
scheduled at their first cICSI cycle. Thus, at the mo-
ment, it is not justifiable introducing IMSI in the clinical
Fig. 2 Data synthesis for the main reproductive outcome measures of the published RCTs on unselected infertile populations
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practice and that procedure should be performed only in
a research setting with the aim to clarify its real efficacy
in well selected populations.
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